Immuron Ltd (IMRN) SEC filings

IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026Score 4/30

$0.88−0.03 (-3.52%)

Close on Nov 13, 2026Market cap $7.06MP/E –Yield –

SEC filings

40 of Immuron's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	6-K	Oct 27, 2026	Oct 28, 2026	SEC EDGAR
Current report	6-K	Oct 27, 2026	Oct 27, 2026	SEC EDGAR
Current report	6-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Current report	6-K	Oct 22, 2026	Oct 22, 2026	SEC EDGAR
Current report	6-K	Oct 16, 2026	Oct 16, 2026	SEC EDGAR
Current report	6-K	Oct 13, 2026	Oct 13, 2026	SEC EDGAR
Annual report	20-F	Jun 30, 2026	Sep 24, 2026	SEC EDGAR
Current report	6-K	Sep 24, 2026	Sep 24, 2026	SEC EDGAR
Current report	6-K	Sep 22, 2026	Sep 22, 2026	SEC EDGAR
Current report	6-K	Sep 4, 2026	Sep 4, 2026	SEC EDGAR
Current report	6-K	Aug 28, 2026	Aug 28, 2026	SEC EDGAR
Current report	6-K	Aug 19, 2026	Aug 19, 2026	SEC EDGAR
Current report	6-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	6-K	Jul 27, 2026	Jul 27, 2026	SEC EDGAR
Current report	6-K	Jul 21, 2026	Jul 21, 2026	SEC EDGAR
Current report	6-K	Jul 20, 2026	Jul 20, 2026	SEC EDGAR
Current report	6-K	Jul 16, 2026	Jul 16, 2026	SEC EDGAR
Current report	6-K	Jul 6, 2026	Jul 6, 2026	SEC EDGAR
Current report	6-K	Jun 29, 2026	Jun 29, 2026	SEC EDGAR
Current report	6-K	Jun 23, 2026	Jun 23, 2026	SEC EDGAR
Current report	6-K	Jun 18, 2026	Jun 22, 2026	SEC EDGAR
Current report	6-K	May 28, 2026	May 28, 2026	SEC EDGAR
Current report	6-K	May 8, 2026	May 8, 2026	SEC EDGAR
Current report	6-K	Apr 30, 2026	Apr 30, 2026	SEC EDGAR
Current report	6-K	Apr 17, 2026	Apr 17, 2026	SEC EDGAR
Current report	6-K	Apr 13, 2026	Apr 13, 2026	SEC EDGAR
Current report	6-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	6-K	Feb 27, 2026	Mar 2, 2026	SEC EDGAR
Current report	6-K	Feb 17, 2026	Feb 17, 2026	SEC EDGAR
Current report	6-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Current report	6-K	Feb 9, 2026	Feb 9, 2026	SEC EDGAR
Current report	6-K	Jan 23, 2026	Jan 23, 2026	SEC EDGAR
Current report	6-K	Jan 20, 2026	Jan 20, 2026	SEC EDGAR
Current report	6-K	Jan 14, 2026	Jan 14, 2026	SEC EDGAR
Current report	6-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	6-K	Dec 16, 2025	Dec 16, 2025	SEC EDGAR
Current report	6-K	Dec 15, 2025	Dec 15, 2025	SEC EDGAR
Current report	6-K	Dec 12, 2025	Dec 12, 2025	SEC EDGAR
Current report	6-K	Dec 10, 2025	Dec 10, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Immuron's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IMRN.

Compare: IMRN vs RANI · IMRN vs ALMS · IMRN vs ISCO · IMRN vs APLM · IMRN vs EVMN

Revenue growth5.9% · median 3.4%

Operating margin-49.9% · median -530.5%

Net margin-47.7% · median -493.0%

Company	Revenue	Growth
ISCO	$9.51M	+3.4%
IMRN	A$7.71M	+5.9%
ALMS	$7.24M	–
RANI	$6.58M	+448.7%
APLM	–	–
EVMN	$0	-100.0%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 7
Held by institutions: 0.0%
Auditor: GRANT THORNTON AUDIT PTY LTD
SEC CIK: 1660046

Advertisement
300 × 250

See a number that looks wrong?